A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Arthritis, Lupus, Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery, Immunology / Infectious Diseases, Rheumatology |
| Healthy: | No |
| Age Range: | 18 - 50 |
| Updated: | 5/30/2018 |
| Start Date: | January 8, 2018 |
| End Date: | March 25, 2018 |
An Open-Label, Single-Sequence Study to Investigate the Effects of BMS-986165 on the Single-Dose Pharmacokinetics of Methotrexate in Healthy Male Subjects
The purpose of this study is to investigate effects of BMS-986165 on blood levels of
methotrexate given as a single dose in healthy male patients.
methotrexate given as a single dose in healthy male patients.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
visit www.BMSStudyConnect.com
Inclusion Criteria:
- Body Mass Index (BMI): 18.0 - 32.0 kg/m2
- Normal renal function at screening
Exclusion Criteria:
- Any medical condition that presents a potential risk to the participant and/or that
may compromise the objectives of the study, including active, or history of, liver
disease
- Any contraindication indicated in the MTX package insert
- History or presence of chronic bacterial or viral infection
- History or presence of an autoimmune disorder
- Any significant acute or chronic medical illness
- Active TB requiring treatment or documented latent TB within the previous 3 years
- Current or recent (within 3 months of study treatment administration) gastrointestinal
disease that could affect absorption
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
1
site
Click here to add this to my saved trials
